Finally, the committee agree that genetic assessment for AML should be repeated in cases of disease relapse to demonstrate clonal evolution of the disease, including acquisition of chromosomal abnormalities, the disappearance or appearance of somatic mutations, including FLT3 mutations, where the emergence of mutated clones paves the way for the delivery of new FLT3 inhibitors given as single agents, as gilteritinib. This evidence concerns the gene FLT3 and acute myeloid leukemia.